Effectiveness of Dupilumab Treatment to Treat Chronic Rhinosinusitis With Nasal Polyposis: A Systematic Review and Meta-Analysis

Background and Objectives: Evidence bearing on the safety efficacy of dupilumab treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) has recently been presented by researchers from various institutions. Therefore, we compared to those endoscopic sinus surgery.Methods: The PubMed, Scopus, Embase, Web Science, Cochrane databases were searched independently two authors dates their inception December 2022. We retrieved clinical results CRSwNP patients after administration, including changes in patient symptoms effects quality life, (treatment group) surgery (control group).Results: Eight articles (1,251 patients) ultimately included. Dupilumab significantly improved (nasal congestion) (mean difference [MD], -1.4433; 95% confidence interval [CI], -1.7233 -1.1632; I<sup>2</sup>=94.2%), visual analog sinusitis score (MD, -5.0506; CI, -5.4744 -4.6267; I<sup>2</sup>=84.0%), olfactory function (standardized MD, 1.2691; 1.1549 1.3833; I<sup>2</sup>=18.4%), life (SNOT-22 score) -34.4941; -39.4187 -29.5695; I<sup>2</sup>=90.8%), Lund-Mackay computed tomography -7.2713; -8.9442 -5.5984; I<sup>2</sup>=87.7%), polyp -3.1021; -3.7066 -2.4977; I<sup>2</sup>=95.6%) at about 12 months pretreatment values. Compared surgery, similarly 1.9849; -1.6190 5.5888; I<sup>2</sup>=0.0%) but was less effective terms reducing SNOT-22 3.8472; 1.9872 5.7073; I<sup>2</sup>=96.7%) congestion 0.6519; 0.5619 0.7420; I<sup>2</sup>=97.7%).Conclusion: reduced subjective symptom scores objective measures progression preoperative